Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
株価
$0.25974701
最終同期: 2025-01-06
時価総額
$2.04M
変化(1日)
0.74%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)の利益
Jun 2024 時点の利益 TTM: $-12.93M
Acticor Biotech SAS の最新の財務報告によると、同社の現在の利益は $-12.93M です。2022 年には $-19.33M の利益を上げ、これは 2021 年の利益 $-16.54M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Acticor Biotech SAS の利益の推移(2010 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -40,906.21%
US
$1.95B -15,190.08%
NL
$-4.02B 30,968.98%
AU
$-3.09B 23,780.79%
US
- -
CH